The active ingredient in Irfen Dolo L is ibuprofen, a commonly used member of the non-steroidal anti-inflammatory drug (NSAID) class. This medication is applied across therapeutic domains for its analgesic (pain-relieving), antipyretic (fever-reducing), and anti-inflammatory roles.

It generally plays a role in managing symptoms related to physical discomfort and symptoms that create noticeable physiological strain. Irfen Dolo L is commonly used to help with may assist with symptoms related to minor aches and pains, such as headache, muscular aches, toothache, and menstrual cramps. It is also a relevant therapeutic option for easing symptoms related to inflammatory or irritative states, such as the pain and stiffness associated with conditions involving episodic or fluctuating manifestations like rheumatoid arthritis and osteoarthritis. In clinical settings that involve acute or unstable symptom patterns, it is relevant when supportive symptom management is appropriate.

Addressing symptom clusters that may become intense or disruptive, this medication is commonly used to help with minor aches, physical discomfort, and fever, providing support that helps ease the overall symptom burden. The drug is relevant for easing discomfort linked to fever and may assist with mild to moderate pain from conditions like headaches, muscle aches, dental pain, and menstrual cramps. This assistance helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Symptoms that interfere with daily functioning

Regulatory References

1. MedlinePlus Drug Information

This section outlines the official eligibility and non-eligibility criteria for Irfen Dolo L (Ibuprofen) based on governmental regulatory information.

Contraindications (Must NOT Use)

Use is strictly contraindicated for several populations, including patients with a known hypersensitivity to Ibuprofen, Aspirin, or other NSAIDs. The medicine is also prohibited for those with severe organ failure (heart, renal, or hepatic), active gastrointestinal bleeding, or a history of recurrent peptic ulceration. It is also contraindicated following Coronary Artery Bypass Graft (CABG) surgery.

Age and Pregnancy Restrictions

• Children: The use of adult-strength formulations (e.g., 400 mg) is generally contraindicated in children under 12 years of age or under 40 kg body weight, as safety and efficacy are often not established in this age group.
• Pregnancy: Use is contraindicated from the 20th week of pregnancy onward due to the risk of fetal kidney problems (oligohydramnios) and premature closure of the fetal ductus arteriosus.
• Breastfeeding: Use is generally allowed as Ibuprofen is excreted into breast milk in very low, non-harmful concentrations.

Conditional Use and Special Caution

Eligibility is restricted for elderly patients, who must use the lowest effective dose for the shortest duration. Caution is also required for patients with pre-existing conditions like uncontrolled hypertension, mild-to-moderate renal or hepatic impairment, or a history of specific gastrointestinal diseases (e.g., Crohn’s disease), as these conditions may require specialized monitoring.

Documented Interactions with Other Medicines and Products

Official regulatory information describes specific interaction patterns for the active ingredient, Ibuprofen, which necessitate co-administration restrictions.

Contraindicated and High-Risk Combinations

The co-administration of Irfen Dolo L with other NSAIDs, including other ibuprofen-containing products and COX-2 selective inhibitors, is explicitly restricted. This prohibition is established due to an officially documented, significantly increased risk of serious gastrointestinal adverse events, such as ulceration, bleeding, or perforation.

Interactions Affecting Drug Concentrations

Ibuprofen may reduce the renal clearance of certain co-administered medicines, leading to increased plasma concentrations. This pharmacokinetic interference applies to drugs such as Lithium, Methotrexate, and Cardiac Glycosides (e.g., Digoxin), potentially resulting in higher systemic exposure of these substances.

Interactions Affecting Therapeutic Effect and Safety

• Anticoagulants and SSRIs: Co-administration with anticoagulants (e.g., Warfarin), anti-platelet agents, and Selective Serotonin Reuptake Inhibitors (SSRIs) is associated with an officially documented, compounded risk of gastrointestinal bleeding or haemorrhage.
• Antihypertensives and Diuretics: Ibuprofen may diminish the intended therapeutic effects of ACE Inhibitors, ARBs, Beta-blockers, and Diuretics, potentially resulting in reduced control of blood pressure or reduced fluid clearance, as noted in regulatory text.

Timing and Substance Constraints

For patients taking immediate-release low-dose aspirin for cardioprotection, regulatory data suggests Ibuprofen may competitively inhibit its anti-platelet effect. To avoid this timing-sensitive interaction, Ibuprofen should be taken at least 8 hours before or at least 30 minutes after the immediate-release aspirin dose. Concomitant use with Alcohol is noted to increase the occurrence of undesirable effects, particularly involving the GI tract or central nervous system.

The interaction profile indicates that patients who are elderly or have pre-existing renal impairment are at a documented increased risk of interaction-related adverse events.

Irfen Dolo L exerts its effects through a non-selective, reversible inhibition of Cyclooxygenase (COX) enzymes (COX-1 and COX-2). This molecular action is the fundamental step in several cascading physiological modulations, which are further optimized by the drug's specialized formulation.

---

The primary mechanism involves the S-Ibuprofen moiety blocking the COX enzymes, restricting the synthesis of prostaglandins ( PGE2, PGI2). This inhibition reduces the sensitization threshold of peripheral nociceptors and modulates local vascular responses (edema and vasodilation) at sites of COX-2 induction. The active molecule also crosses into the central nervous system to reduce PGE2 synthesis within the hypothalamus.

This molecular dampening results in the biological resetting of the elevated thermal set-point triggered by pyrogens, which facilitates the engagement of physiological mechanisms that dissipate heat.

---

The incorporation of lysine creates a salt form that dramatically enhances the water solubility of Ibuprofen. This unique kinetic property ensures the rapid systemic delivery of the active molecule, enabling effective COX inhibitory concentrations to be reached rapidly compared to the dissolution of the Ibuprofen acid form. This design directly accelerates the time required for the entire cascade of physiological modulations to begin.

How to Use Irfen Dolo L

The administration of Irfen Dolo L (Ibuprofen-Lysinat) is governed by the guidance for its oral film-coated tablet form. The official instructions define the required dosage range, frequency, and duration for its appropriate short-term use, as outlined in official prescribing information.

---

Official Administration Guidelines

Instruction Domain	Official Regulatory Principle
Route and Form	The medicine must be administered orally and the film-coated tablets must be swallowed whole with water. Tablets should not be chewed, crushed, or sucked.
Dosing Schedule	A single dose ranges from 200 mg to 400 mg of Ibuprofen. The total daily intake is strictly limited, and must not exceed 1200 mg in any 24-hour period for self-medication.
Frequency and Interval	Doses may be taken up to three or four times daily, provided a minimum interval of 4 to 6 hours is maintained between administrations.
Intake Context	It is generally recommended to take the tablet with or after food, a consideration often emphasized for individuals with gastric sensitivity.
Duration Principle	The medication is explicitly intended for short-term use only. For self-medication, use should not exceed 3 days for fever or 3 to 4 days for pain without medical supervision.

---

Population and Procedural Rules

The overarching procedural instruction for all patients is to utilize the lowest effective dose for the shortest duration necessary, a standard principle for NSAID administration. While no specific numerical dose reduction is required for older adults or adolescents (ge 40 kg), this emphasis on minimal dosage is particularly stressed. If a dose is missed, the next dose should maintain the necessary 4-to-6-hour minimum time interval, strictly prohibiting the taking of a double dose.

Research evidence / Overview of studies for Irfen Dolo L

---

Evidence for use in Acute Pain and Fever Relief

The core clinical evaluation was conducted using Randomized Controlled Trials (RCTs), a study design used for acute pain models. These trials explored short-term or episodic symptom patterns and examined outcomes related to physical discomfort and systemic or functional imbalance (fever).

Findings describe patterns observed in studies comparing the formulation to a non-active placebo. An RCT comparing the ibuprofen-lysine salt to standard ibuprofen acid reported a finding of non-inferiority when measuring the overall change in pain intensity over a six-hour period.

---

Studies on Formulation and Onset of Action

Research explored the pharmacokinetic properties related to the rate at which the active compound was observed to be absorbed by the body. Comparative clinical trials examined whether this accelerated absorption was associated with a measurably faster change in patient-reported outcomes describing perceived discomfort than standard ibuprofen.

Systematic reviews described patterns where changes in symptom intensity were observed earlier. However, some RCTs reported no statistically significant difference in the measured time until clinical onset, and the findings related to clinical onset appear to be inconsistent across all measured studies.

---

What is still uncertain about Irfen Dolo L

A primary area of uncertainty involves the practical clinical relevance of the rapid absorption properties, as non-uniformity exists regarding whether faster absorption translates into a consistently faster change in patient-reported outcomes. Core studies are short-term, providing limited insight into long-term changes or outcomes reflecting daily functioning.

Specific evidence for older adults and certain subgroups remains limited. Pharmacokinetic studies also reported that the specific properties of faster absorption are markedly different when the formulation is administered after a meal compared to the effect observed when fasting.

Key Studies & References Ibuprofen: MedlinePlus Drug Information (General Information and Background Efficacy)

Common questions about Irfen Dolo L (FAQ)

---

Q: Does Irfen Dolo L contain an analgesic (painkiller)?

A: Yes, Irfen Dolo L contains ibuprofen lysine, which is classified as a non-steroidal anti-inflammatory drug (NSAID) with analgesic properties. According to official product information, this means the active substance works to relieve pain as well as reduce inflammation and fever.

---

Q: Is Irfen Dolo L available in different strengths or formulations?

A: Regulatory documents indicate that Irfen Dolo L is available as film-coated tablets containing 400 mg of the active substance. The formulation uses ibuprofen lysine, which is a form of ibuprofen designed for absorption.

---

Q: What is the primary role of the ingredient ibuprofen lysine?

A: The primary role of ibuprofen lysine is to serve as the active ingredient that provides the drug's therapeutic effects. This specific form of ibuprofen (ibuprofen combined with the amino acid lysine) is formulated to potentially allow for rapid absorption compared to standard ibuprofen. Regulatory information indicates that this formulation is designed to support a potentially faster onset of its analgesic (pain-relieving) and anti-inflammatory action.

---

Q: Can Irfen Dolo L cause stomach bleeding or ulcers?

A: As with many NSAIDs, official safety information indicates that Irfen Dolo L can potentially cause serious gastrointestinal issues, including stomach bleeding or ulcers. Regulatory warnings indicate that this risk is a consideration, particularly for individuals with a history of gastrointestinal conditions. This potential side effect is noted as being related to how NSAIDs can affect the stomach lining.

---

Q: Can Irfen Dolo L be taken for headaches?

A: Yes, Irfen Dolo L is officially indicated for the treatment of various pain types, including headaches. According to the regulatory documents, its analgesic properties make it suitable for relieving mild to moderate pain.

---

Q: What is the general regulatory guidance if an accidental overdose occurs?

A: If a patient accidentally takes an overdose of Irfen Dolo L, the regulatory guidance is to seek immediate medical attention. Taking too much of the medicine can lead to serious side effects. The official product information emphasizes the need to immediately contact a doctor or hospital in the event of an overdose.

---

Q: What is the general regulatory guidance for a missed dose?

A: Official product information on Irfen Dolo L indicates that if a dose is missed, the recommended course of action is generally to continue with the next scheduled dose. Regulatory documents advise against taking a double dose to compensate for a missed one, as this practice may increase the risk of side effects.

Storage and Temperature Requirements

Official labeling for Ibuprofen-Lysinat products mandates storage at a controlled room temperature, typically between 15 C and 30 C. The tablets must be protected from both light and moisture to maintain product stability and must be kept in their original packaging until the labeled expiration date. It is a mandatory safety instruction that the medicine be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Irfen Dolo L must be disposed of in accordance with local regulatory requirements. The product should not be discarded via household waste or flushed down the sink or toilet, as this may lead to environmental contamination. The preferred method of disposal is through a designated drug take-back program or a pharmacy collection point.